Sectivia

DexComDXCM

NASDAQ · USA · Segment 1 of 8 in the Medicine, pharma & life science value chain: Diabetes & metabolic disease

Continuous glucose monitoring for people with diabetes: the G-series sensors, and Stelo, which is sold over the counter.

Diabetes & metabolic disease: Treatment and monitoring of diabetes and metabolic disease, from insulin to glucose monitoring.

Key metrics

Market cap
$34.5B
Price
$91.06
Today
−1.4%
Return YTD
+39.1%
Return 1Y
+14.5%
P/E
34.5
P/S
6.9
P/B
13.2

Data as of 2026-08-25 · updates daily after U.S. close

Theme exposure

DiabetesGlucose monitoringMedtech exposureDigital health

In the value chain

Products & services

  • CGM sensors (G-series)
  • Stelo (OTC)
  • Diabetes software

Competitors

Risks

  • Price competition
  • Reimbursement changes

Supply chain

Supplies →

Full supply chain for DXCM →

Same segment: Diabetes & metabolic disease

Compare DXCM

See where DexCom sits in the full Medicine, pharma & life science map: every segment from upstream suppliers to end markets, with daily metrics.Open the Life science value chain →